RT Journal Article
T1 Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
A1 Salvador-Martín, Sara
A1 Raposo-Gutiérrez, Irene
A1 Navas-López, Víctor Manuel
A1 Gallego-Fernández, Carmen
A1 Moreno-Álvarez, Ana
A1 Solar-Boga, Alfonso
A1 Muñoz-Codoceo, Rosana
A1 Magallares, Lorena
A1 Martínez-Ojinaga, Eva
A1 Fobelo, María J.
A1 Millán-Jiménez, Antonio
A1 Rodriguez-Martinez, Alejandro
A1 Vayo, Concepción A.
A1 Sánchez, Cesar
A1 Tolin, Mar
A1 Bossacoma, Ferrán
A1 Pujol-Muncunill, Gemma
A1 González de Caldas, Rafael
A1 Loverdos, Inés
A1 Blanca-García, José A.
A1 Segarra, Oscar
A1 Eizaguirre, Francisco J.
A1 García-Romero, Ruth
A1 Merino-Bohórquez, Vicente
A1 Sanjurjo-Sáez, María
A1 López-Fernández, Luis A.
K1 Biomarker
K1 Gene expression
K1 Infliximab
K1 Adalimumab
K1 Ulcerative colitis
K1 Crohn’s disease
AB Around a 20-30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2-∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies.
PB MDPI
YR 2020
FD 2020-05-09
LK http://hdl.handle.net/10668/3700
UL http://hdl.handle.net/10668/3700
LA en
NO Salvador-Martín S, Raposo-Gutiérrez I, Navas-López VM, Gallego-Fernández C, Moreno-Álvarez A, Solar-Boga A, et al. Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease. Int J Mol Sci. 2020 May 9;21(9):3364
DS RISalud
RD Sep 17, 2025